AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05352633
Drug: Intensive BP Arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in the Intensive BP treatment group have a goal of SBP \<120 mmHg. It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed. The local investigator may select among the available study antihypertensive medications. Other drugs not supplied by the trial may also be used as the investigator determines appropriate. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals: Angiotension converting enzyme (ACE)-inhibitors;Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics
Trial: NCT05660746
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Conventional dosing. Induction: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance: 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 μg/mL.~Precision dosing. Induction: 5-12.5 mg/kg at 0, 2, and 6 weeks to target a week6 concentration of 18-24 μg/mL with dosing support provided by the RoadMABTM clinical decision support tool. Maintenance: 5-15 mg/kg every 4-8 weeks to achieve apriori pharmacokinetic and pharmacodynamic targets (CRP, disease activity scores and fecal calprotectin) with dosing support provided by the RoadMABTM clinical decision support tool.
Trial: NCT05150340
Drug: TAK-771
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
Trial: NCT05067309
Drug: Letrozole 2.5mg
RxNorm normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Missed abortion received letrozole then misoprostol
Trial: NCT06489548
Drug: Foralumab TZLS-401 50 µg
RxNorm normalized name: Foralumab
DrugBank: Foralumab (DB16170)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foralumab is a nasal anti-CD3 antibody. It will be administered in doses of 50 µg vs. placebo.
Trial: NCT06489548
Drug: Foralumab TZLS-401 100 µg
RxNorm normalized name: Foralumab
DrugBank: Foralumab (DB16170)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foralumab is a nasal anti-CD3 antibody. It will be administered in doses of 100 µg vs. placebo.
Trial: NCT04696952
Drug: Zopiclone
RxNorm normalized name: zopiclone
DrugBank: Zopiclone (DB01198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zopiclone
Trial: NCT04725214
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib With STUPP Regimen
Trial: NCT05686928
Drug: Cetaphil Healing Ointment
RxNorm normalized name: Petrolatum 71.5% Topical application Ointment [CETAPHIL HEALING OINTMENT]
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ointment application twice daily
Trial: NCT05180994
Drug: Topical infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab eye drops (10mg/ml) administered four (4) times per day for three (3) months.
Trial: NCT04805333
Drug: Artemisia annua 450mg
RxNorm normalized name: Artemisia annua pollen
DrugBank: Artemisia annua pollen (DB10582)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
Trial: NCT04805333
Drug: Artemisia annua 900mg
RxNorm normalized name: Artemisia annua pollen
DrugBank: Artemisia annua pollen (DB10582)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
Trial: NCT00811031
Drug: Taxotere
RxNorm normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m\^2 Day 1 of every 21-day cycle by vein for 4 cycles prior to surgery.
Trial: NCT04805333
Drug: Artemisia annua 1350mg
RxNorm normalized name: Artemisia annua pollen
DrugBank: Artemisia annua pollen (DB10582)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
Trial: NCT00811031
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg twice a day by mouth.
Trial: NCT04805333
Drug: Artemisia annua 1800mg
RxNorm normalized name: Artemisia annua pollen
DrugBank: Artemisia annua pollen (DB10582)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
Trial: NCT04805333
Drug: Artemisia annua - recommended phase II dose
RxNorm normalized name: Artemisia annua pollen
DrugBank: Artemisia annua pollen (DB10582)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisia annua will be self-administered via a preparation of decaffeinated coffee. The dose for this cohort will be based on analysis of previous cohorts.
Trial: NCT05142423
Drug: AK109+AK104
RxNorm normalized name: Immunoglobulin g1, anti-(human vascular endothelial growth factor receptor 2) (human monoclonal ak109 .gamma.1-chain), disulfide with human monoclonal ak109 .kappa.-chain, dimer
DrugBank: Pulocimab (DB18938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It includes dose escalation and dose expansion stage. 6-12 patients will be enrolled in dose escalation stage for safety and efficacy. Then select specific dose of AK104 and AK109. Expand for the further safety and efficacy study.
Trial: NCT06087601
Drug: 0.9% Sodium chloride
RxNorm normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: us-guided bilateral genicular nerves sham block with 0,5ml 0,9% normal saline
Trial: NCT06087601
Drug: 95% ethanol
RxNorm normalized name: ALCOHOL 95 mL in 100 mL TOPICAL SOLUTION [95% Ethanol (190 Proof)]
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: us-guided bilateral genicular nerves neurolysis with 0,5ml 95% ethanol
Trial: NCT04895358
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT04895358
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT04895358
Drug: dextrose
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT06006169
Drug: BL-B01D1
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BL-B01D1 was administered by intravenous infusion on D1, D8, or D1 in 3-week cycles.
Trial: NCT06006169
Drug: SI-B003
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SI-B003 was administered intravenously every 3 weeks (Q3W).
Trial: NCT05970354
Drug: EMLA Cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eutectic Mixture of Local Anesthetics (Lidocaine 2.5% and Prilocaine 2.5%)
Trial: NCT06413108
Drug: TB31F
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: transmission-blocking monoclonal antibody TB31F
Trial: NCT04776135
Drug: MT-1186
RxNorm normalized name: lipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension
Trial: NCT05145283
Drug: Conestat alfa (Ruconest®)
RxNorm normalized name: conestat alfa
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: In the current study, participants will receive two intravenous injections of conestat alfa (immediately during the TAVI procedure and again 3h later) at a dose of 100 U/kg (first dose) and of 50 U/kg (subsequent dose), for patients less than 84 kg; two intravenous injections (immediately during the TAVI procedure and again 4h later) of conestat at a dose of 8400 U (4 vials, first dose) and of 4200 U (2 vials, subsequent dose) for patients of 84 kg body weight or greater. The chosen regimen including repeated administration should increase and maintain serum C1INH levels above twice the serum concentration for six to eight hours in the majority of patients. The timeframe of therapeutic concentrations will cover the period of the TAVI procedure itself and the immediate postprocedural period during which reperfusion and additional ischemic events related to global hypoperfusion may occur.
Trial: NCT06533098
Drug: Nipocalimab
RxNorm normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nipocalimab will be administered intravenously.
Trial: NCT06533098
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone will be administered orally.
Trial: NCT04707300
Drug: Human T Lymphoid Progenitor (HTLP) injection
RxNorm normalized name: human cord blood hematopoietic progenitor cell
DrugBank: Human cord blood hematopoietic progenitor cell (DB11054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The HTLP cell suspension will be injected intravenously at the time of UCB HSCT on D0
Trial: NCT05682222
Drug: EDP1815
RxNorm normalized name: EDP1815
DrugBank: EDP1815 (DB16486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP1815 is an essentially non-viable, non-replicating pharmaceutical preparation of a single strain of Prevotella histicola, a naturally occurring human commensal microbe.
Trial: NCT06565689
Drug: YK012
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells
Trial: NCT04937452
Drug: Rotigotine 4Mg/24Hrs Patch
RxNorm normalized name: ROTIGOTINE 4MG/24HRS PATCH
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rotigotine 4 mg/24Hrs administration for 24 weeks
Trial: NCT04937452
Drug: Rotigotine 6Mg/24Hrs Patch
RxNorm normalized name: ROTIGOTINE 6MG/24HRS PATCH
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rotigotine 6 mg/24Hrs administration for 24 weeks
Trial: NCT06327724
Drug: Belimumab
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Start of new treatment due to active disease
Trial: NCT00710216
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg/day
Trial: NCT00710216
Drug: Telbivudine
RxNorm normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 600 mg/day
Trial: NCT06067698
Drug: Mesalamine and alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine 1000 mg every 8 hrs. + alpha-lipoic acid 600 mg once daily for 3 months
Trial: NCT06650605
Drug: 123I-ATT001
RxNorm normalized name: 123I-
DrugBank: 123I-iodometomidate (DB13021)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 123I-ATT001
Trial: NCT06207656
Drug: EBC
RxNorm normalized name: Nebcin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive the following per 28-day cycle:~* Encorafenib: 300 mg (4 × 75 mg oral capsule) daily (QD)~* Binimetinib: 45 mg (3 × 15 mg oral tablet) twice daily (BID)~* Cetuximab: 500 mg/m2 every 2 weeks as per standard institutional practice.
Trial: NCT04917406
Drug: Application of lidocaine together with dexamethasone
RxNorm normalized name: dexamethasone / lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% is applied on the positive pole while dexamethasone 4 mg/ml is applied on the negative pole. Through the use of current the drugs penetrate the fascia.
Trial: NCT05012670
Drug: [14C]-Paxalisib Capsule
DrugBank: Paxalisib (DB15186)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive a single dose 15 mg (NMT 3.5 MBq), administered orally in the fasted state with with 240 mL water.
Trial: NCT06014515
Drug: 18F-FDG
RxNorm normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
Trial: NCT04719156
Drug: Indocyanine green solution administered at 2.0mg/kg.
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosing of ICG to be administered at 2.0mg/kg, two hours prior to surgery.
Trial: NCT05890729
Drug: XTMAB-16 or Placebo
RxNorm normalized name: XTMAB-16
DrugBank: XTMAB-16 (DB18380)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion
Trial: NCT05911594
Drug: Solifenacin group
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive medical treatment (Solifenacin 5 mg once or twice daily) without any second line of treatment
Trial: NCT05911594
Drug: Intradetrusor BOTOX group
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Patients in this group will receive Intradetrusor BOTOX after failure of medical
Trial: NCT05251779
Drug: Bergamot essential oils
RxNorm normalized name: BERGAMOT OIL
DrugBank: Bergamot oil (DB14335)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group will be given Bergamot essential oils for inhalation.
Trial: NCT05132803
Drug: HPV 16 TA-CIN
RxNorm normalized name: CIN-QUIN
DrugBank: TA-CIN (DB05809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No dose escalation or reduction
Trial: NCT04855201
Drug: Bocidelpar
RxNorm normalized name: Bocidelpar
DrugBank: Bocidelpar (DB16906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT05874518
Drug: The treatment with letrozole tablets was started on the fifth day of the menstrual cycle
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole tablets were given at 2.5mg (Jiangsu Hengrui Pharmaceutical Co., Ltd., H19991001, 2.5mg per tablet), po (oral), qd, for 5-7 consecutive days. When the diameter of follicles reaches 18mm, Chorionic gonadotrophin is given at 5000u (Lizhu Group Lizhu Pharmaceutical Factory, Chinese medicine H44020668, 5000u per branch), with intramuscular injection, qd, to promote follicle discharge. Patients were also instructed to have sexual intercourse on the same day and on day 2.
Trial: NCT05509192
Drug: MTPI
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients from both study groups will receive premedication in the usual fashion, typically 0-2 mg of IV midazolam at the discretion of the care team. Patients in both study groups will receive 1 mg/kg of lidocaine intravenously, followed by an opioid such as fentanyl (1-2 mcg/kg), prior to administration of induction drugs. Patients assigned to MTPI will then be given rocuronium (0.6mg/kg), followed by propofol intravenously as a single bolus within 10 seconds. A typical propofol bolus for induction ranges from 1-2mg/kg, depending on the patient's age, medical history, and co-morbidities. Propofol dosing will be at the discretion of the care team. Patients will count down from one hundred. Once apnea occurs, as indicated by a lack of respiratory effort, the eyes will be taped, and intubation with C-MAC (Karl Storz 8403ZX, Tuttlingen, Germany) is initiated.
Trial: NCT06300307
Drug: ATX-01
RxNorm normalized name: ATX-01
DrugBank: ATX-01 (DB18141)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion
Trial: NCT05694026
Drug: Diquafosol tetrasodium
RxNorm normalized name: diquafosol tetrasodium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
Trial: NCT05504876
Drug: Midazolam Syrup
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered Midazolam Syrup 5 mg orally once daily in fed state;
Trial: NCT05312801
Drug: BAFF CAR-T
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous CAR-T cell therapy expressing the BAFF-ligand.
Trial: NCT06323265
Drug: Adebrelimab + chemotherapy
RxNorm normalized name: menthol
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab: 1200mg, d1, iv (30-60min), Q3W ,up to progressive disease or toxicity intolerable Chemotherapy: etoposide 100mg/m2，d1-3，iv；carboplatin AUC=5-6，d1，iv；or cisplatin 75mg/m2，d1，iv，Q3W，4 cycles；
Trial: NCT06580444
Drug: Brexanolone
RxNorm normalized name: Brexanolone
DrugBank: Brexanolone (DB11859)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The participant will receive either a placebo, or 90, 60, or 30 mcg/kg/hr of Brexanolone over a 20-hour period intravenous infusion.
Trial: NCT06579144
Drug: Efanesoctocog alfa
RxNorm normalized name: Efanesoctocog alfa
DrugBank: Efanesoctocog alfa (DB16662)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
Trial: NCT06580145
Drug: L-leucine
RxNorm normalized name: L-Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-leucine is an essential amino acid used to competitively inhibit kynurenine uptake into the brain via the large neutral amino acid transporter (LAT1).~The proposed dose for L-leucine is 4.31 g/day, administered orally.
Trial: NCT06580145
Drug: L-lysine
RxNorm normalized name: L-Lysine
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-lysine monohydrochloride is also an essential amino acid. It serves as an active comparator to control for general effects on brain protein synthesis and enters the brain through separate cationic amino acid transporters.~The proposed dose for L-lysine is 6 g/day, administered orally
Trial: NCT04633187
Drug: EDP-938
RxNorm normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP-938 800mg~Dose adjustments were made for subjects taking azole antifungals.
Trial: NCT06023758
Drug: KN026
RxNorm normalized name: ANTI-HER2 BSAB KN026
DrugBank: Anbenitamab (DB18411)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KN026：30 mg/kg Q3W
Trial: NCT06023758
Drug: KN046
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: KN046：5 mg/kg Q3W
Trial: NCT04874311
Drug: Bintrafusp alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bintrafusp alfa will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 2400 mg.
Trial: NCT04608539
Drug: Ferric Derisomaltose
RxNorm normalized name: ferric derisomaltose
DrugBank: Ferric derisomaltose (DB15617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intravenous infusion, 20 mg/kg body weight, postoperative day 1
Trial: NCT04608539
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral therapy, 100 mg twice daily, from postoperative day 4 until 4-week follow-up
Trial: NCT05569174
Drug: secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AIN457 300 mg subcutaneously for 12 weeks
Trial: NCT00101140
Drug: anti-thymocyte globulin
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00101140
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00101140
Drug: thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04764825
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dosage administered differ in regards to age and tolerance to opioids:~0.2 mg/kg: all patients \<65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily.~0.15 mg/kg: Opioid naive patients \> 65 years of age.
Trial: NCT04764825
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dosage administered differ in regards to age and tolerance to opioids:~0.2 mg/kg: all patients \<65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily.~0.15 mg/kg: Opioid naive patients \> 65 years of age.
Trial: NCT06102824
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800-1200mg/m2, IV, days 1, 8, q3w
Trial: NCT06102824
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-35mg/m2, IV, days 1 and 8, q3w
Trial: NCT06102824
Drug: Eribulin
RxNorm normalized name: Eribulin
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1.4mg/m2, IV, days 1 and 8, q3w